Design of phase II ALS clinical trials. (Q53220635)

12 May 2018

title

Design of phase II ALS clinical trials. (English)

1 reference

12 May 2018

amyotrophic lateral sclerosis

main subject

phase II clinical trial

0 references

1 reference

2

Merit Cudkowicz

1 reference

12 May 2018

author name string

David A Schoenfeld

series ordinal

1

1 reference

12 May 2018

publication date

1 January 2008

1 reference

12 May 2018

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

published in

1 reference

12 May 2018

volume

9

1 reference

12 May 2018

issue

1

1 reference

12 May 2018

page(s)

16-23

1 reference

12 May 2018

Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity

cites work

1 reference

https://api.crossref.org/works/10.1080%2F17482960701875896

Neuroprotective agents for clinical trials in ALS: a systematic assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960701875896

Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960701875896

Amyotrophic lateral sclerosis: recent insights from genetics and transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960701875896

Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960701875896

Selecting promising ALS therapies in clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960701875896

A randomized sequential trial of creatine in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960701875896

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960701875896

A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960701875896

A simple algorithm for designing group sequential clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960701875896

Group sequential clinical trials with triangular continuation regions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960701875896

When (not) to stop a clinical trial for benefit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960701875896

Pro/con clinical debate: It is acceptable to stop large multicentre randomized controlled trials at interim analysis for futility. Pro: Futility stopping can speed up the development of effective treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960701875896

An overview of group sequential methods in longitudinal clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960701875896

The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960701875896

Functional outcome measures as clinical trial endpoints in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960701875896

A clinical trial of creatine in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960701875896

An efficient multi‐stage, single‐arm Phase II futility design for ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960701875896

Improving efficiency of ALS clinical trials using lead‐in designs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960701875896

10.1080/17482960701875896

21 January 2018

Identifiers

DOI

1 reference

12 May 2018

PubMed ID

18273715

1 reference

12 May 2018